LY3885125 / Eli Lilly - LARVOL DELTA

A Study of LY3885125 in Participants with Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - P1 | N=49 | Terminated | Sponsor: Eli Lilly and Company | N=112 ➔ 49 | Active, not recruiting ➔ Terminated; Participants were not dosed in Part B as per the protocol, the patient population will be refined and new outcome measures will be applied in a separate study.

Enrollment change • Trial termination • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - P1 | N=112 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease